Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
about
Animal models of hemophiliaGene therapy for hemophiliaLong-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.Advancements in gene transfer-based therapy for hemophilia A.Inhibitors - cellular aspects and novel approaches for tolerance.Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.Donor antigen-primed regulatory T cells permit liver regeneration and phenotype correction in hemophilia A mouse by allogeneic bone marrow stem cells.Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.Strategies to target long-lived plasma cells for treating hemophilia A inhibitors.Immunomodulation for inhibitors in hemophilia A: the important role of Treg cellsProgress toward inducing immunologic tolerance to factor VIII.Inhibitors - genetic and environmental factors.In vivo induction of regulatory T cells for immune tolerance in hemophilia.Factor VIII inhibitors: Advances in basic and translational science.Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B.Induction of tolerance to factor VIII by transient co-administration with rapamycin.Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopesAdvances in Overcoming Immune Responses following Hemophilia Gene Therapy.B-cell-delivered gene therapy induces functional T regulatory cells and leads to a loss of antigen-specific effector cells.Tilt balance towards regulation: evolving new strategy for treatment of hemophilia inhibitors.A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.Platelet Gene Therapy Promotes Targeted Peripheral Tolerance by Clonal Deletion and Induction of Antigen-Specific Regulatory T Cells
P2860
Q27012571-F9259EB4-E8BA-4DBB-89F1-327FBEE0EF30Q28081911-D9FE787B-F78D-4358-BE6E-57A6230ED089Q33748093-0722A2FA-F7FA-4E89-A697-A706D65CC211Q33923877-3FC7A60D-3061-4B6E-B320-C7601CB31A64Q34380850-F86836D5-6BE4-4536-AC57-3DD19D394AABQ34541550-B93C1936-E432-4C0C-9A9A-1AB7C028DEAEQ35144444-D2013E11-8CC0-43C0-82F7-F97E698F73D5Q35885551-E0CDA560-5860-494F-8226-5EE0553E9F74Q36294778-12093C10-DF5A-4A14-BD2F-92CD276BD8D6Q36832899-ACBC9282-9733-4200-A57B-BE37D0A56EFEQ37803130-66F957D8-D0B7-4D25-B374-929446960823Q38090391-A405CFDB-E416-479D-869F-171A9937D479Q38206856-14894DF9-EBC7-4E02-B57C-187999D0ED34Q38574966-9F85696B-EDBD-4A7F-A177-CE02E34632D5Q39266287-A5CEFFC3-9201-445E-8BC4-13E1627A5D7FQ40485786-D6F3CE46-A0B9-4722-80F6-869E2E1E6551Q41824863-5CEF96C9-E82D-4486-9030-21BD7D0CE6E0Q41907025-1B50F268-BD61-4A2E-875B-61893537F8F6Q42209182-7E55AFAE-8A02-4681-B3AB-EAED7E3F204DQ42502298-060F082F-9E57-41E7-971F-A430A276513DQ42839182-4186DC76-EBD4-438E-BED3-18E5F7BAB7EDQ45868319-0497C1AB-AB00-4FE0-A396-383B3A3DB559Q45870660-849AF2F9-8989-4CC0-AFC9-91C197B993C7Q45870677-895C56AB-673F-4F52-8DE8-42842B24332BQ58761368-814E6916-FEB4-4E01-B68B-6BB97A48B174
P2860
Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-CD3 antibodies modulate a ...... plasmid-mediated gene therapy.
@en
Anti-CD3 antibodies modulate a ...... plasmid-mediated gene therapy.
@nl
type
label
Anti-CD3 antibodies modulate a ...... plasmid-mediated gene therapy.
@en
Anti-CD3 antibodies modulate a ...... plasmid-mediated gene therapy.
@nl
prefLabel
Anti-CD3 antibodies modulate a ...... plasmid-mediated gene therapy.
@en
Anti-CD3 antibodies modulate a ...... plasmid-mediated gene therapy.
@nl
P2093
P2860
P921
P1433
P1476
Anti-CD3 antibodies modulate a ...... plasmid-mediated gene therapy.
@en
P2093
Baowei Peng
Carol H Miao
David J Rawlings
Hans D Ochs
Peiqing Ye
P2860
P304
P356
10.1182/BLOOD-2009-05-217315
P407
P577
2009-09-21T00:00:00Z